LONG BRANCH, N.J., June 10 /PRNewswire/ -- The world antibody community will convene in Long Branch, NJ on September 12-13 to attend and network at the "2nd International Trends in Antibody Deal-Making & Financing Summit," announces Strategic Research Institute.
The conference follows the extremely successful April inaugural meeting in San Diego.
The meeting is but the first of THE WORLD ANTIBODY SUMMIT, a four-conference series of related antibody conferences to take place from September 12 until September 19. The SUMMIT will take place at the Ocean Place Conference & Beach Resort in Long Branch, NJ.
The other SUMMIT meetings are:
ENGINEERED ANTIBODIES, September 16-18 -- Contact: Mark Alexay at
malexay@srinstitute.com
ANTIBODY MANUFACTURING & PRODUCTION, September 18-19 -- Contact:
Ed Drilon at edrilon@srinstitute.com
DISPLAY TECHNOLOGIES, September 18-19 -- Contact: Glenn Pascual at
gpascual@srinstitute.com
The finance and deal-making conference attracts a very broad and international constituency of venture capitalists, other investors, analysts, antibody companies, and an array of pharmaceutical company executive business development personnel. They will be in attendance to study increasing capital movements in this sector, investment trends, financing options, deal structures, and partnering strategies. As new antibody technologies continue to be developed and new therapies emerge, the pharmaceutical industry is competing for access to them and investors to finance the lucrative opportunities.
The conference is organized into 3 main sections: 1) Early Stage & Mid-Size Antibody Companies: The Next Generation, 2) Future Trends in Antibody Deal-Making & Collaborations, & 3) The Effect of Deal Structures, Alliances & Market Issues on Antibody Drug Development.
Participants include: Abbott Bioresearch, Abgenix, Altus Biologics, Amersham Biosciences, Amgen, Applied Molecular Evolution, Athersys Inc., Bayer, Bioscience Ventures Inc., Cambridge Antibody Technology, Centocor, Corixa Corporation, Dyax Corporation, Eli Lilly & Company, Epitomics Inc., Foresight Strategies, Genentech, ICOS Corporation, IDEC Pharmaceuticals, Merrill Lynch, Peregrine Pharmaceuticals, Raven Biotechnologies, Redington Inc., RBC Capital Partners, Seattle Genetics, Signet Laboratories, Synergy Capital Partners, Vaccinex Inc., Viventia Biotech, Xerion Pharmaceuticals.
Three important panels will be featured entitled, "What is Happening in the Antibody Dx Arena?," "What are Antibody Deals Delivering?" & "Where's All The Money Gone, When Will Wall Street Re-embrace the Antibody Markets?"
The lead sponsor for the meeting & host of the gala reception is Amersham Biosciences.
To request the agenda in PDF format, please contact Ed Drilon at edrilon@srinstitute.com or 212-967-0095 x233. Include your fax number, affiliation and mailing address.
To register for the exposition or inquire about sponsorship opportunities to augment your company's on-site exposure to prospective clients and collaborators, please contact Mark Alexay at malexay@srinstitute.com or 212.967.0095 x251. |
